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BSE Meeting at CDC
The recent report of a new variant of
Creutzfeldt-Jakob disease (V-CJD) in Great Brit-
ain and the possible link between the disease and
bovine spongiform encephalopathy (BSE) has
raised a number of health and safety concerns
(1,2). On April 8, 1996, CDC organized a meeting
of U.S. agency representatives to review informa-
tion about the report of U.K. cases and about
efforts to identify the existence of BSE and V-CJD
in the United States. The meeting covered the
scientific evidence for the report of V-CJD; recom-
mendations from a meeting of international ex-
perts organized by the World Health Organization
on April 2-3; and the current and proposed activi-
ties of U.S. agencies with regard to BSE and
V-CJD.
Among the observations made during the meet-
ing were the following:
• There is no evidence from U.S. surveillance
activities or from scientific studies to indicate
that BSE exists in the United States.
• Active surveillance for BSE is conducted by the
U.S. Department of Agriculture (USDA). All
cattle presented for slaughter in the United
States are observed for signs of central nervous
system (CNS) disorders. Livestock showing
CNS signs are condemned and not allowed to
enter the slaughter plant or to become part of
the human food supply. Since 1990, laboratory
testing of nearly 2,800 brain specimens from
cattle with CNS signs has shown no evidence of
BSE.
• No U.K. cattle or ruminant-based feed has been
imported into the United States since July
1989, when USDA banned the importation of
cattle and cattle products from the United
Kingdom. U.K. cattle imported before the ban
will be destroyed as a precaution to ensure that
these animals do not enter the food chain (hu-
man or animal).
• The Food and Drug Administration plans to
issue a ban on ruminant-to-ruminant feeding in
the United States.
• Additional research is needed on the charac-
terization of the causative agent of BSE and on
the epidemiology, rapid laboratory diagnosis,
and pathogenesis of BSE and CJD.
• The Centers for Disease Control and Preven-
tion (CDC) monitors the occurrence of CJD in
the United States through surveillance and
special epidemiologic studies (3). On the basis
of mortality surveillance from 1979 to 1993, the
annual incidence of CJD remained stable at
approximately one case per million persons. In
the United Kingdom, five of eight patients who
died of V-CJD since May 1995 were younger
than 30 years of age; by comparison, in the
United States, CJD deaths among persons
younger than 30 years are extremely rare
(fewer than 5 per billion per year). CDC’s efforts
will be expanded to include active surveillance
studies at four Emerging Infections Program
sites (Connecticut, Minnesota, Oregon, and the
San Francisco area) and in Atlanta to provide
more up-to-date information on the occurrence
of CJD and to verify the absence or presence of
V-CJD.
Future cooperative efforts among U.S. agen-
cies, industry, and other interested parties in re-
sponse to the report of V-CJD are planned. The
report of the April 8 meeting at CDC can be
accessed on the CDC NCID Web site (connect to
http://www.cdc. gov/ncidod/ncid.htm; the report is
under New, Reemerging, and Drug-Resistant In-
fections).
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CDC Foundation Supports Emerging
Infectious Disease Projects
The National Foundation for the Centers for
Disease Control and Prevention, Inc. (NFCDC), a
not-for-profit corporation established by Congress
to support CDC’s mission, announced in August
1995 that one of its initial funding efforts would
be in the area of antibiotic-resistant diseases.  
 Also in the area of infectious diseases, NFCDC
has recently received a gift from a Pennsylvania
foundation to establish fellowships for two repre-
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